drugset / Trial / NCT00456859
Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease
RandomizedParallel-groupOpen-labelTreatment
Summary
The CAP-KD trial is a prospective, multicenter, randomized, open-label, two-arm, parallel group comparison clinical trial and will be conducted as a researcher-directed study to assess the efficacy of Kremezin in preventing the progression of CKD. We compare two groups of patients: those receiving conventional treatment alone and those receiving such treatment paired with Kremezin.
Timeline
- Start
- 2004-04
- Primary completion
- —
- Completion
- 2007-09
Outcome
Missed primary endpoint
paper event-free survival (P = 0.9) did not differ between groups. PMID 19615804 ↗
paper AST-120 did not substantially slow the progression of kidney disease in patients with moderate to severe CKD during 1 year. PMID 19615804 ↗
Publications
- Background Morita S, Fukuhara S, Akizawa T, Asano Y, Kurokawa K. Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD). Clin Exp Nephrol. 2005 Sep;9(3):219-27. doi: 10.1007/s10157-005-0358-7.
- Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, Gejyo F, Matsuo S, Yorioka N, Kurokawa K; CAP-KD Study Group. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009 Sep;54(3):459-67. doi: 10.1053/j.ajkd.2009.05.011. Epub 2009 Jul 17.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Activated Charcoal | Other / unclassified | 6 g | Oral |